Liposomal Bupivacaine Versus Standard Bupivacaine Plus Dexamethasone in Quadriceps Sparing Femoral Nerve Block and Wound Infiltration for Total Knee Arthroplasty

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

January 1, 2020

Conditions
OsteoarthritisPain, Postoperative
Interventions
DRUG

Liposomal bupivacaine

Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.

DRUG

Bupivacaine plus dexamethasone

Bupivacaine HCl 0.5% 10 mL plus dexamethasone 2 mg for quadriceps sparing femoral nerve block and bupivacaine HCl 0.25% plus dexamethasone 2 mg for posterior knee compartment periarticular injection

Trial Locations (1)

12208

Albany Medical Center, Albany

Sponsors
All Listed Sponsors
lead

Albany Medical College

OTHER